Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended January 31, 2001 (Fiscal Q1 2001)
Business Overview: Cooper develops, manufactures, and markets healthcare products through two primary segments: CooperVision (CVI), specializing in contact lenses, and CooperSurgical (CSI), focusing on women's healthcare diagnostic and surgical products.
Key Financial Metrics
| Metric | Q1 2001 | Q1 2000 |
|---|---|---|
| Net Sales | $48.9 million | $40.4 million |
| Gross Profit | $32.1 million | $26.6 million |
| Gross Margin | 66% | 66% |
| Operating Income | $9.7 million | $8.2 million |
| Net Income | $6.3 million | $4.4 million |
| Diluted EPS | $0.43 | $0.31 |
| Operating Cash Flow | $2.5 million | $5.3 million |
| Cash and Equivalents (End of Period) | $12.0 million | $2.7 million |
| Total Debt | $61.0 million | $48.4 million (Oct 31, 2000) |
| Debt-to-Equity Ratio | 0.30:1 | 0.24:1 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 21% year-over-year, driven by a 57% surge in CSI revenue (largely due to acquisitions) and an 11% increase in CVI revenue.
- Profitability: Operating income rose 17% to $9.7 million. Diluted earnings per share increased 26% to $0.43.
- Segment Performance:
- CVI: Core business grew 15% (28% in constant currency). U.S. revenue grew 14%, while international revenue grew 17% despite currency headwinds. OEM sales declined 71%.
- CSI: Revenue grew 57%, with acquisitions accounting for 52% of the growth. Margins declined from 56% to 53% due to lower-margin acquired products.
- Unusual Items:
- Gain on Investment: Recorded a $719,000 gain in "Other income" from the Quidel acquisition of Litmus Concepts, where Cooper held a preferred equity position.
- Integration Costs: Incurred approximately $700,000 in additional SGA costs related to the integration of recent CSI acquisitions.
- Cash Flow: Operating cash flow decreased to $2.5 million from $5.3 million, primarily due to inventory builds for new product launches and payments for bonus plans and dispute settlements.
Guidance, Outlook, and Risks
- Dividend: The Board approved an increase in the annual dividend from 8 cents to 10 cents per share, payable in semiannual installments.
- Liquidity: Management expects existing cash ($12 million) and operating cash flow to fund operations, capital expenditures, and smaller acquisitions. A $35.1 million line of credit remains available under the KeyBank facility.
- Outlook: CSI is expected to continue consolidating the women's healthcare market through acquisitions. CVI margins are viewed as attainable barring major mix changes. The effective tax rate is estimated at 33% for the full fiscal year, with a long-term target of approximately 30%.
- Risks:
- Currency: Exposure to foreign exchange fluctuations, particularly the British pound sterling, which weakened against the U.S. dollar.
- Integration: Risks associated with acquisition integration delays or costs.
- Market Conditions: Potential impact of new competitors, technologies, or regulatory issues.
Investor Verification Checklist
- Verify the sustainability of CSI's 57% revenue growth, noting that 52% was acquisition-driven and margins temporarily declined.
- Confirm the impact of the $719,000 one-time gain on the Litmus transaction on net income and EPS.
- Monitor the integration progress of recent CSI acquisitions (Leisegang and MedaSonics) to assess if margins will return to historical levels.
- Review the $3.5 million cash outflow for dispute settlements and its potential recurrence.
- Assess the effect of foreign currency weakness on CVI's international revenue growth versus constant currency growth.